SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

SAN FRANCISCO -- Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free survival (PFS) in patients with unresectable hepatocellular ...

Lenvima plus Keytruda with TACE significantly improved progression-free survival in unresectable, non-metastatic hepatocellular carcinoma compared to TACE with placebo. The study reported a median ...

A meta-analysis found that patients with early and intermediate-stage hepatocellular carcinoma who received external beam radiation therapy (EBRT) demonstrated better local control and ...

SAN FRANCISCO — Adding transarterial chemoembolization (TACE) to treatment with lenvatinib (Lenvima) significantly improved survival compared to levantinib alone in patients with advanced ...

Hepatocellular carcinoma (HCC) poses a substantial health burden globally, with liver cancer being the fourth most common cause of cancer-related mortality worldwide. In China, where the incidence of ...

Abscopal effect refers to the shrinkage or regression of metastatic tumours that are distant from the irradiated field.